Suscribirse

Viewpoint: Stroke Prevention in Recent Guidelines for the Management of Patients with Atrial Fibrillation: An Appraisal - 27/09/17

Doi : 10.1016/j.amjmed.2017.02.026 
Tatjana S. Potpara, MD, PhD a, b, Gregory Y.H. Lip, MD a, c, d, , Carina Blomström-Lundqvist, MD, PhD e, Chern-En Chiang, MD f, A. John Camm, MD g
a School of Medicine, Belgrade University, Serbia 
b Cardiology Clinic, Clinical Center of Serbia, Belgrade 
c Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom 
d Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark 
e Department of Cardiology, Institution of Medical Science, Uppsala University, Sweden 
f General Clinical Research Center and Division of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University, Taiwan 
g Cardiology Clinical Academic Group, St. George's University of London, United Kingdom 

Requests for reprints should be addressed to Gregory Y.H. Lip, MD, Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom.Institute of Cardiovascular SciencesUniversity of BirminghamUnited Kingdom

Abstract

Formal guidelines play an important role in disseminating the best available evidence knowledge and are expected to provide simple and practical recommendations for the most optimal management of patients with various conditions. Such guidelines have important implications for many disease states, which thereby could be more professionally managed in everyday clinical practice by clinicians with divergent educational backgrounds, and also more easily implemented in wards or outpatient clinics, eliminating inequalities in health care management. In this brief Viewpoint we provide an appraisal on the recommendations pertinent to the prevention of atrial fibrillation–related stroke or systemic thromboembolism, as provided in recently published guidelines for the management of this arrhythmia.

El texto completo de este artículo está disponible en PDF.

Keywords : Atrial fibrillation, Guidelines, Stroke prevention


Esquema


 Funding: None.
 Conflict of Interest: TSP has received speaker fees from Pfizer, Bayer, and Boehringer Ingelheim; and is on the local scientific advisory board for Boehringer Ingelheim in Serbia. GYHL is a consultant for Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife, and Daiichi-Sankyo; and is a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche, and Daiichi-Sankyo; no fees are received personally. CB-L is on the advisory board for Bayer, Pfizer, Sanofi, Medtronic, Boston, and MSD. C-EC has received honoraria for lectures from AstraZeneca, Bayer, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi, Daiichi-Sankyo, Roche, Servier, Tanabe, TTY, and Takeda; and is on the advisory boards for Astra Zeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, MSD, Novartis, Pfizer, and Sanofi. AJC is a consultant for Armetheon, Bayer, BMS/Pfizer, Boston Scientific, Biotronik, Medtronic, Boehringer Ingelheim, Daiichi-Sankyo, and St. Jude Medical; and is a speaker for Bayer, BMS/Pfizer, Medtronic, Daiichi-Sankyo, and St. Jude Medical.
 Authorship: All authors had access to the data and a role in writing the manuscript.


© 2017  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 130 - N° 7

P. 773-779 - juillet 2017 Regresar al número
Artículo precedente Artículo precedente
  • False and Misleading Information About Lyme Disease
  • Eugene D. Shapiro, Phillip J. Baker, Gary P. Wormser
| Artículo siguiente Artículo siguiente
  • Associated Risk of Malignancy in Patients with Cardiovascular Disease: Evidence and Possible Mechanism
  • Tal Hasin, Zaza Iakobishvili, Giora Weisz

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.